|
| 36331676 | Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors. | Invest New Drugs | 2023 |
| 37609177 | Impact of <i>KRAS</i> Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. | Res Sq | 2023 |
| 37541273 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. | Lancet Oncol | 2023 |
| 37058010 | Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). | Clin Cancer Res | 2023 |
| 37119430 | Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. | J Gastrointest Cancer | 2023 |
| 37314501 | A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. | Cancer Chemother Pharmacol | 2023 |
| 37311055 | A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. | Oncologist | 2023 |
| 37339271 | Discordance of HER2 Expression and/or Amplification on Repeat Testing. | Mol Cancer Ther | 2023 |
| 37276871 | Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. | Lancet Oncol | 2023 |
| 37072571 | Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. | NPJ Precis Oncol | 2023 |
| 36970876 | Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors. | Cancer | 2023 |
| 37099736 | Adagrasib in Advanced Solid Tumors Harboring a <i>KRAS</i><sup><i>G12C</i></sup> Mutation. | J Clin Oncol | 2023 |
| 37092904 | The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers. | Clin Cancer Res | 2023 |
| 37026453 | Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized Clinical Trial. | Ann Surg | 2023 |
| 36751659 | Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. | J Immunother Precis Oncol | 2023 |
| 36882377 | A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors. | Cancer | 2023 |
| 36649067 | Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. | Ann Surg | 2023 |
| 36423446 | Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. | Gynecol Oncol | 2023 |
| 36658425 | Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. | Nat Med | 2023 |
| 34362693 | Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. | Clin Genitourin Cancer | 2022 |
| 35775636 | Precision Oncology With Germline and Somatic Sequencing in Pancreatic Cancer: The Time Is Now. | Pancreas | 2022 |
| 35767205 | First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors. | Invest New Drugs | 2022 |
| 35610322 | Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. | Sci Rep | 2022 |
| 35834760 | Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. | JCO Precis Oncol | 2022 |
| 35849783 | Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer. | Cancer Discov | 2022 |
| 35655320 | A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. | J Exp Clin Cancer Res | 2022 |
| 36400106 | Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. | Lancet Oncol | 2022 |
| 35908677 | 3D bioprinted poly(lactic acid)/mesoporous bioactive glass based biomimetic scaffold with rapid apatite crystallization and in-vitro Cytocompatability for bone tissue engineering. | Int J Biol Macromol | 2022 |
| 35863672 | Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. | Int J Radiat Oncol Biol Phys | 2022 |
| 36030462 | A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors. | Cancer Chemother Pharmacol | 2022 |
| 36282600 | 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. | J Clin Invest | 2022 |
| 34980020 | PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. | BMC Cancer | 2022 |
| 35312753 | Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. | Clin Cancer Res | 2022 |
| 34995974 | Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. | Surg Oncol | 2022 |
| 35058326 | Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. | J Immunother Cancer | 2022 |
| 35171660 | Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With <i>IDH</i>-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. | JCO Precis Oncol | 2022 |
| 34705134 | Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. | Invest New Drugs | 2022 |
| 31274655 | Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. | Ann Surg | 2021 |
| 35663531 | Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. | J Immunother Precis Oncol | 2021 |
| 33686452 | A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. | Invest New Drugs | 2021 |
| 33909232 | Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. | Invest New Drugs | 2021 |
| 33870151 | First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. | EClinicalMedicine | 2021 |
| 33783054 | Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. | Oncologist | 2021 |
| 33929876 | Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. | Am Soc Clin Oncol Educ Book | 2021 |
| 33885205 | Pancreas Cancer-Associated Pain Management. | Oncologist | 2021 |
| 33771853 | A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. | Clin Cancer Res | 2021 |
| 34853384 | Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. | NPJ Precis Oncol | 2021 |
| 34972968 | Immunotherapy in Gastrointestinal Malignancies. | Adv Exp Med Biol | 2021 |
| 34790391 | Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. | J Gastrointest Oncol | 2021 |
| 34725215 | Letter to the editor from Pant <i>et al</i>. | J Immunother Cancer | 2021 |